32. Prioritize the pediatric TB diagnostic space to ensure there are improved tools for pediatric TB infection and disease detection to reach and maintain targets.

​

33. Develop quality-assured, affordable, less invasive alternative specimen processing methods or products (not based only on sputum) that can be used for the pediatric population, such as urine, stool or saliva.

​

34. Ensure diagnostic studies include children and alternative (non-sputum-based) sample types.

​

35. Expedite development of point-of-care biomarker-based tests for infants and children.

​

36. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, all-inclusive pricing models, for both laboratory-based and point-of-care technologies.

​

37. Provide service level agreements that clearly spell out key performance indicators for all technology types and their offered service plans, plus a mitigation plan when the threshold is exceeded.

 

66. Prioritize regulatory approvals where required for introduction of Truenat TB tests in additional high TB burden countries. 

​

67. Share a plan for service and  other forms of technical support in international settings with international partners for comment and transparent review/ implementation.

​

68. Proactively define standardized Key Performance Indicators for system and test performance. 

​

69. Prioritize the regulatory processes of HIV assays for infant diagnosis and viral load. 

​

70. Offer access pricing and prospective reductions based on global volume thresholds; publish the volumes procured quarterly.

​

71. Prioritise the development of resistance markers for TB as well as multiple sample types and to work on a TB +COVID test.

​

​